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ABSTRACT
OBJECTIVES
To develop and validate a genetic tool to predict age 
of onset of aggressive prostate cancer (PCa) and to 
guide decisions of who to screen and at what age.
DESIGN
Analysis of genotype, PCa status, and age to 
select single nucleotide polymorphisms (SNPs) 
associated with diagnosis. These polymorphisms 
were incorporated into a survival analysis to estimate 
their effects on age at diagnosis of aggressive PCa 
(that is, not eligible for surveillance according 
to National Comprehensive Cancer Network 
guidelines; any of Gleason score ≥7, stage T3-T4, 
PSA (prostate specific antigen) concentration ≥10 
ng/L, nodal metastasis, distant metastasis). The 
resulting polygenic hazard score is an assessment of 
individual genetic risk. The final model was applied 
to an independent dataset containing genotype and 
PSA screening data. The hazard score was calculated 
for these men to test prediction of survival free 
from PCa.
SETTING
Multiple institutions that were members of 
international PRACTICAL consortium.
PARTICIPANTS
All consortium participants of European ancestry with 
known age, PCa status, and quality assured custom 
(iCOGS) array genotype data. The development 
dataset comprised 31 747 men; the validation dataset 
comprised 6411 men.
MAIN OUTCOME MEASURES
Prediction with hazard score of age of onset of 
aggressive cancer in validation set.
RESULTS
In the independent validation set, the hazard score 
calculated from 54 single nucleotide polymorphisms 
was a highly significant predictor of age at diagnosis 
of aggressive cancer (z=11.2, P<10−16). When men in 
the validation set with high scores (>98th centile) were 
compared with those with average scores (30th-70th 
centile), the hazard ratio for aggressive cancer was 
2.9 (95% confidence interval 2.4 to 3.4). Inclusion of 
family history in a combined model did not improve 
prediction of onset of aggressive PCa (P=0.59), and 
polygenic hazard score performance remained high 
when family history was accounted for. Additionally, 
the positive predictive value of PSA screening 
for aggressive PCa was increased with increasing 
polygenic hazard score.
CONCLUSIONS
Polygenic hazard scores can be used for personalised 
genetic risk estimates that can predict for age at onset 
of aggressive PCa.
Introduction
Prostate cancer (PCa) is a major health problem, with 
over a million new cases and over 300 000 associated 
deaths estimated worldwide in 2012.1 An international 
randomised controlled trial showed that screening 
for prostate specific antigen (PSA) resulted in a 27% 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Screening for prostate cancer (PCa) with tests for prostate specific antigen 
(PSA) can lead to early detection and allow for curative treatment, but universal 
screening also has considerable disadvantages for the men who might never 
develop aggressive disease
Ideally, physicians would identify and screen patients at high risk of developing 
aggressive PCa or PCa at a young age
A practical clinically useful tool to predict age of onset is not yet available
WhAT ThIS STudy AddS
This study presents and validates a novel polygenic hazard score that is an 
indicator of age at onset of aggressive PCa
The score is a relatively inexpensive assessment of an individual man’s age 
specific risk and provides objective information on whether a given patient might 
benefit from PSA screening
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reduction in PCa mortality.2 Because of concerns over 
a high rate of false positive results, in addition to 
aggressive treatment of apparently indolent disease, 
however, many clinical guidelines do not endorse 
universal screening and instead stress the importance 
of taking into account individual patient risk factors 
to decide whether to screen.3-5 The goal is to avoid 
unnecessary screening while still identifying men at 
high risk for whom screening and early detection can 
reduce morbidity and mortality.
A patient’s genetic predisposition could be critical to the 
decision of whether and when to offer screening. Genome-
wide association studies (GWAS) have shown genetic 
variants associated with increased risk of PCa.6 7 These 
developments, combined with the recent accessibility 
of genotyping, provide an opportunity for cancer 
screening informed by genetic risk.8 With a combination 
of risk information from an array of single nucleotide 
polymorphisms (SNPs), polygenic models can estimate 
an individual’s genetic risk for developing the disease.9 
Predicted polygenic risk could improve clinical decisions 
such as who to screen for PCa and at what age.10 11
We used data from 31 747 men of European ancestry 
from the international PRACTICAL consortium (http://
practical.ccge.medschl.cam.ac.uk/) to develop a 
polygenic hazard score (PHS) for predicting age related 
risk of developing aggressive PCa. This is designed 
for use before the decision of whether to screen (for 
example, with PSA) by providing a risk stratification 
strategy to maximise screening efficiency. The hazard 
score was tested in data from an independent screening 
study (UK ProtecT12), with the hypothesis that it would 
be an indicator of a patient’s inherent genetic risk for 
developing PCa at various ages in his lifetime and thus 
could guide PSA screening.
Methods
Definition of aggressive disease
Concerns about overdiagnosis and overtreatment of 
indolent disease have influenced discussion of PCa 
screening, whereas there is consensus that aggressive 
cancer warrants treatment.13 14 When possible, we 
therefore focus validation in this study on prediction 
of aggressive disease, defined as any tumour that 
would require radical treatment for a typical healthy 
man according to guidelines from the National 
Comprehensive Cancer Network (NCCN)—that is, 
not eligible for active surveillance.14 This includes 
cancers with any of Gleason score ≥7, stage T3-T4, 
PSA concentration ≥10 ng/mL, nodal metastasis, or 
distant metastasis. Stage T2 tumours were classified 
without a subcategory in our database, so a patient 
with low Gleason score and low PSA concentration but 
stage T2b or T2c would be considered low risk in this 
analysis even though NCCN guidelines would indicate 
treatment for intermediate risk; this was to ensure 
that no low risk tumours were included as cases of 
aggressive cancer.
Some additional analyses used age of diagnosis 
of any PCa (rather than only aggressive PCa) as 
complementary information. Another secondary 
analysis tested prediction for “very aggressive disease,” 
defined as any of Gleason score ≥8, stage T3-4, positive 
nodes, or distant metastases.
Participants
Development set
To develop the polygenic hazard score model, we 
obtained genotype and data on age from 21 studies from 
the PRACTICAL consortium (table A in appendix 1), 
representing 31 747 men (18 868 with any PCa, 10 635 
with aggressive PCa, 5406 with very aggressive PCa, 
12 879 controls) of genotypic European ancestry. Age 
was either at diagnosis or last follow-up (for controls). 
Genotyping, performed with a custom Illumina array 
(iCOGS), and quality control steps have been described 
previously.6 A total of 201 043 single nucleotide 
polymorphisms were available for analysis. We could not 
categorise cancer as aggressive or not in 4803 of the men 
with cancer because of incomplete data on staging; these 
were excluded from analyses of aggressive cancer.
Validation set
An independent study examined performance of the 
model. The validation set came from the ProtecT study, 
which screened 82 429 men with PSA testing and 
found 8891 men with PSA concentration over than 
the specified threshold of 3.0 ng/L or higher, 2896 
of whom received a diagnosis of PCa.12 Among those 
individuals, we obtained data on genotype and age for 
6411 men (1583 with any PCa, 632 with aggressive 
PCa, with 220 very aggressive PCa, 4828 controls). 
Staging data were available for all cases. This dataset 
was selected for validation because PSA results were 
also available for all participants at time of either 
diagnosis or interview. Further details in appendix 1.
Missing data
During model development, we excluded single 
nucleotide polymorphisms with call rates less than 
95%. We imputed missing calls for the remaining 
polymorphisms with the mean genotype count for that 
allele across all participants.
Polygenic hazard score
The polygenic hazard score was developed previously 
as a parsimonious survival analysis model to predict 
the time to event outcome (in this case, age of onset of 
PCa). It has been published elsewhere,15 and further 
details of application here are described in appendix 1.
The score is defined as the vector product of a 
patient’s genotype (Xi) for n selected single nucleotide 
polymorphisms and the corresponding parameter 
estimates (i) from a Cox proportional hazards regression 
(see equation).
PHSx =        Xiβi
n
i
Σ
Genetic prediction specifically for aggressive PCa 
has proved elusive, with most single nucleotide 
polymorphisms associated with aggressive disease also 
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showing association with any PCa.16 Therefore, in the 
interest of maximising power to select polymorphisms 
associated with age of onset, we decided to initially 
include all cases from the development set (that is, 
any PCa) for generation of the model. We then tested 
an alternate strategy that limited generation to cases of 
aggressive cancer for comparison. The primary metric 
for validation in both instances remained prediction 
for aggressive cancer in the independent validation set.
To verify whether the polygenic hazard score 
accurately predicts age at onset of aggressive PCa, we 
calculated the score for all patients in the validation 
set and tested it as the sole predictive variable in a 
Cox proportional hazards regression model for age 
of diagnosis. Patients in the validation set with a 
diagnosis of low risk disease (Gleason score ≤6, PSA 
concentration <10 ng/L, and stage T2N0M0 or lower) 
were censored at time of diagnosis, reflecting the 
fact that it is unknown if they would later receive a 
diagnosis of aggressive disease or at what age that 
might have occurred. Significance was set at α of 0.01 
for this and all subsequent Cox models. As an indicator 
of effect size for the model, we calculated a hazard 
ratio comparing men with high scores (>98th centile) 
with those with average risk (30th-70th centile). All 
hazard ratios presented here refer to the same pattern: 
high versus average risk.
Because of evidence that initially low risk disease 
often progresses to require treatment,17-19 and because 
this might be particularly important for men with a 
diagnosis at a young age, we performed a secondary 
analogous analysis to test for prediction of age of 
diagnosis of any PCa. We did a secondary analysis for 
prediction of very aggressive disease.
To further assess the clinical significance of the 
polygenic hazard score, we looked at the positive 
predictive value (PPV) of PSA testing within the 
validation set, with clinical diagnosis (including 
biopsy result) as the ideal. We posited that risk 
stratification by centiles of the score would reflect the 
underlying incidence of PCa and therefore also affect 
the positive predictive value of PSA testing. Details 
on the calculation of positive predictive value are in 
appendix 1. Categories of the score were designated by 
centile compared with the young healthy population 
within the development set—that is, those controls 
aged <70. All centiles reported in this manuscript refer 
to this population.
To visualize distribution of the polygenic hazard 
score among cases of aggressive PCa in the validation 
set, we generated a Lorenz curve.20-22
Comparison with family history
One of the most important risk factors used currently 
for screening decisions is family history.3 We compared 
family history and polygenic hazard score for 
prediction of onset of aggressive PCa using the same 
Cox model approach as before, with the 5703 men 
(1405 with any PCa, 554 with aggressive PCa, 4298 
controls) from men in the validation set with known 
family history status (none or one or more affected first 
degree relatives). Models were constructed with family 
history alone, hazard score alone, or with both. These 
were compared via log likelihood tests.
Patient involvement
No patients were directly involved in designing the 
research question or in conducting the research. A 
link to the published results will be posted on the 
PRACTICAL consortium website, and the respective 
principal investigators of each contributing study will 
be provided the results to disseminate to individual 
participants when possible.
Results
Model development
Of the 201 043 single nucleotide polymorphisms 
included in the dataset, 2415 were associated with 
increased risk of PCa in the trend test, with P<10−6. 
The stepwise regression framework then identified 
54 of these polymorphisms that were incorporated 
into the Cox proportional hazards model (table B 
in appendix  1). The 54 parameter estimates (for 
the hazard of developing PCa) were combined with 
individual genotype to generate the polygenic hazard 
score. Figure 1 shows Kaplan-Meier and Cox regression 
estimates for the final model. The final model performed 
well for prediction of age at onset of aggressive PCa in 
the development set (z=37.5, P<10−16, hazard ratio 
2.3, 95% confidence interval 2.2 to 2.4).
We excluded only 43 polymorphisms (0.02%) for 
low call rate during model development and used 
imputation for missing calls for 0.4% of calls in the 
final model. Of the 6411 participants in the validation 
set, the median individual polymorphism call rate was 
100%, with a minimum of 98%.
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Fig 1 | Kaplan-Meier and Cox estimates of prostate 
cancer-free survival for patients in development set by 
centile ranges of polygenic hazard score. Centiles are in 
reference to distribution of score within 11 190 controls 
aged under 70 in development set. Time of “failure” 
is age at any diagnosis of prostate cancer. Controls 
were censored at age of observation. Formal testing of 
proportionality is described in appendix 1
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Risk prediction with polygenic hazard score
In the independent validation set from the ProtecT 
study, a Cox proportional hazards model showed 
that the polygenic hazard score was a significant 
predictor of age at onset of aggressive PCa (z=11.2, 
P<10−16). Compared with average risk, the hazard 
ratio for men with a high score (>98th centile) was 2.9 
(95% confidence interval 2.4 to 3.4). The score was 
also predictive of any PCa (z=15.4, P<10−16; hazard 
ratio 2.5, 2.2 to 2.8) and very aggressive PCa (z=6.8, 
P<10−11; 3.0, 2.2 to 4.0).
An alternate model used only cases of aggressive PCa 
from the development set to select polymorphisms. 
Prediction for onset of aggressive PCa was still 
significant (z=9.4, P<10−16, 2.6; 2.1 to 3.1) but did not 
outperform the original model, so we used the original 
for all subsequent analyses as planned.
As the polygenic hazard score was predictive of 
risk of PCa, we expected it to modulate the positive 
predictive value of PSA testing in the validation set. 
Indeed, the positive predictive value of PSA was lower 
among patients with a low score and higher among 
patients with progressively higher scores (fig 2). This 
pattern held for the positive predictive value for any 
PCa, as well (fig B in appendix 1).
The Lorenz curve in figure C in appendix 1 shows the 
distribution of the polygenic hazard score among cases 
of aggressive PCa in the validation set. Patients with 
scores above the 50th centile accounted for 76% of 
cases of aggressive PCa, and the upper fifth accounted 
for 42%.
Family history
With the subset of the validation set with known 
family history status (1405 cases, 4298 controls), 
we repeated the Cox test with adjustment for family 
history. Family history alone was not predictive of 
age of onset of aggressive PCa (z=0.9, P=0.37; hazard 
ratio 1.1, 95% confidence interval 0.9 to 1.4), though 
there was a trend toward prediction for any PCa (z=2.0, 
P=0.05; 1.2, 1.0 to 1.3). Inclusion of family history did 
not improve prediction over the polygenic hazard score 
alone for aggressive PCa (P=0.59) or any PCa (P=0.14), 
and the score remained predictive when adjusted for 
family history.
discussion
PCa risk prediction with polygenic hazard score
Genetic information can guide the decision of 
whether an individual patient needs PCa screening.8 
The polygenic hazard score described here represents 
a personalised genetic assessment of a man’s age 
related risk that could inform both whether and when 
to order screening tests. When applied to data from 
an independent clinical trial, the score was a highly 
significant predictor of age at diagnosis of aggressive 
PCa. Men in the top 2% of the score had a hazard ratio 
of 2.9 for aggressive PCa compared with men with 
average risk. As the score is representative of a man’s 
fixed genetic risk, it can be calculated once, long before 
onset of PCa, and substantially inform the decision of 
whether he should undergo PCa screening.
Positive predictive value is directly dependent on 
prevalence, so if the polygenic hazard score predicts 
age of onset of PCa, the positive predictive value of 
PSA should vary with the score. Figure 2 shows that 
this was true in the validation set. Nearly a quarter of 
the positive PSA test results in men with a high score 
portended a diagnosis of aggressive PCa. The risk was 
much lower for men with low scores with a raised PSA 
concentration. The score is an indicator of the utility of 
PSA screening and could be influential in the decision 
whether to order a PSA test for a given patient.
These results also add to existing data as further 
evidence that genetic features can predict risk of 
PCa.6-8 11 23-25 Investigation into the genotypic features 
described here and elsewhere could give additional 
insight into biological rationales for the association 
with PCa.
The polygenic hazard score is based on hazard ratios 
and is therefore an estimate of relative risk. Absolute 
risk can be estimated within a given population 
if the underlying average hazard rate is known. 
This technique would then allow estimation of an 
individual PCa-free survival curve for any PHS. An 
example of these individual curves has been published 
for Alzheimer’s disease.15
Comparison with family history
Family history of PCa is one of the most commonly 
used risk factors in clinic to determine screening 
decisions.3 Family history, however, was not predictive 
of age of onset of aggressive PCa in the validation set, 
and it did not improve prediction over the hazard score 
alone. This could reflect a lack of power to detect an 
association for family history in the relatively small 
validation set.
Concern of overtreatment
A concern with PSA screening is overdiagnosis and 
overtreatment of indolent disease. As with other genetic 
prediction tools, the polygenic hazard score is not 
specific for aggressive PCa alone,16 though the hazard 
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aggressive PCa in validation set. Centiles refer to 
distribution of polygenic hazard score among young 
controls in development set. 95% confidence intervals 
are from random samples of cases in validation set (see 
methods)
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ratio was slightly higher for aggressive PCa than for 
any PCa. The problem of overdiagnosis is compounded 
by the observation that many men with an initial 
diagnosis of low risk disease later receive a diagnosis 
of aggressive disease.17 19 Active surveillance is one 
answer to overtreatment that avoids up front treatment 
but still allows for monitoring for development of 
indications that treatment is necessary. Indeed, 
most tumours eventually require treatment,17 18 and 
earlier treatment prevents development of metastatic 
disease.18 Hence, avoiding screening altogether in 
patients who might develop PCa at a young age does 
carry risk of considerable morbidity. The present 
results show that the polygenic hazard score can help 
to target screening efforts toward those men at highest 
risk of early onset PCa or aggressive PCa requiring 
treatment.
As the score is predictive of aggressive PCa in general, 
it might also be useful for predicting outcomes of men 
with a diagnosis of low risk PCa in ProtecT. The clinical 
data necessary to answer this interesting question 
have not yet been made available to the PRACTICAL 
consortium, so it will have to be explored in future 
analyses.
Previous tools
Previous studies have used GWAS-associated 
polymorphisms to predict risk of PCa with a case-
control design.23-25 Epidemiological data, however, 
show that risk of PCa is not a simple dichotomy of 
cases and controls but rather is highly dependent 
on increasing age. We therefore opted for a survival 
analysis approach optimised for genetic prediction of 
age of onset of PCa. The polygenic hazard score can 
then be used in clinical decisions, when age plays 
a critical role. If a man has a high risk of developing 
PCa at age 95, this is a different clinical situation from 
a man at high risk at age 55. A comparison of the 
polygenic hazard score with a traditional polygenic 
risk score is described in appendix 2.
Other PCa risk calculators use clinical variables and 
are most useful for a man who might already have 
PCa.26-28 PSA concentration is often included, meaning 
the decision of whether to screen has necessarily 
already been made when the tools are to be used. These 
are less useful for predicting his lifetime risk before he 
reaches an age at which he and his physician have to 
decide whether he should follow some programme of 
PCa screening.
The risk stratification metric with best supportive 
evidence described in the literature is an early midlife 
PSA concentration measured at a relatively young age 
(for example, <50). While not currently recommended 
in many major clinical guidelines,3-5 early midlife PSA 
has been shown to be predictive of future risk of PCa 
and lethal PCa.22 29-31 One nested case-control study 
showed that just the top 10% of the distribution of 
concentrations of PSA in tests done in men aged under 
50 accounted for 40% of cases of metastatic PCa.22 This 
has led to a recommendation to consider PSA testing as 
early as age 45 in men thought by their physician to 
be at high risk.32 A direct comparison of the polygenic 
hazard score and early midlife PSA for prediction of 
age at onset of aggressive PCa would be worthwhile. 
There might also be an advantage to combining the 
two predictors. Unfortunately, early midlife PSA 
concentration was not available in the datasets used in 
the present study so the question is left for future work.
Limitations
The development set was a heterogeneous composite 
of several studies of varied design (table A in appendix 
1), which provides sufficient power to study single 
nucleotide polymorphisms with relatively small effect 
sizes but also raises the concern of undetected bias in 
a retrospective analysis. The validation set, however, 
came from an independent large prospective trial, and 
whatever problems might exist in the development 
set, the most pertinent question is whether the model 
allows useful predictions.
The score was applied here to PSA screening alone. 
PSA is the most prevalent screening test currently for 
PCa, but the hazard score could also be expected to 
add value to other screening strategies, by predicting 
underlying risk of PCa for a given age and therefore 
influencing pretest probability (and, by extension, 
positive predictive value). This might include PSA 
velocity, PSA density, or some screening tool completely 
independent of PSA.
The evidence presented here suggests that the 
polygenic hazard score can help a physician decide 
whether to order PSA, based on the pretest probability 
and positive predictive value of PSA for a given patient. 
Our study does not, however, deal with an alternate 
question: how the hazard score might compare to 
diagnostic tools (including risk calculators) that are 
part of the clinical investigations after a raised PSA 
concentration has been found. Adequate data are 
not available in the present dataset to answer this 
question, but it could be tried in future work as an 
additional application of the polygenic hazard score.
The age range of the validation set was limited to 
50-70; fortunately, this includes the age at which 
screening is believed to have the most benefit.33-36
Finally, ethnicity in this model was limited to 
European ancestry. Validation of the score in other 
ethnic groups—and, if necessary, custom models for 
each—is needed. We plan to investigate this important 
question.
Conclusions
In conclusion, we describe here the development of a 
new polygenic hazard score for personalised genetic 
assessment of individual age associated risk of PCa. 
This score has been validated in an independent 
dataset, showing accurate prediction of onset of 
aggressive PCa. Moreover, the score can predict the 
utility of PSA testing for an individual man. This genetic 
risk model might play a role in guiding decisions about 
whether and when to screen for PCa. Investigation into 
the relation between the score and early midlife PSA 
testing is warranted.
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